MedPath

Effect of Adding Midazolam Versus Fentanyl to Intrathecal Levobupivacaine in Patients Undergoing Caesarean Section

Phase 1
Completed
Conditions
Cesarean Section Complications
Interventions
Registration Number
NCT03824314
Lead Sponsor
Mohamed Abdelrady Mohamed
Brief Summary

The aim of this study is to compare the effects of intrathecal levobupivacaine plus midazolam and levobupivacaine plus fentanyl in patients undergoing caesarean section to get a prolonged postoperative analgesic effect and less side effects

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • Patients of American Society of Anaesthesiologists grades I and II ,
Exclusion Criteria
  • pre-existing neurological or spinal disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group FFentanylgroup F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally. Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
Group MMidazolam. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
Primary Outcome Measures
NameTimeMethod
1st post-operative analgesic request24-hour

pain will be evaluated using VAS score, every 30 min for 180 min then hourly for 12 h and thereafter every 3 hourly till 24 h of surgery in both groups. Rescue analgesia in the form of injection Ketorolac 30mg I.V when VAS \>3 in both groups.

Secondary Outcome Measures
NameTimeMethod
duration of sensory block Total analgesic consumption24-hour

total duration of sensory block (regression to S1 dermatome) will be noted

Trial Locations

Locations (1)

Mohamed

🇪🇬

Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath